GMF(SZ:002551) Sou Hu Cai Jing·2025-08-13 13:10Core Viewpoint - As of August 13, 2025, Shangrong Medical (002551) closed at 4.8 yuan, with a slight increase of 0.42% and a trading volume of 162.11 million shares, resulting in a total transaction value of 754 million yuan [1] Group 1: Financial Performance - Shangrong Medical reported a main revenue of 280 million yuan for Q1 2025, reflecting a year-on-year increase of 1.3% [3] - The net profit attributable to shareholders was 13.96 million yuan, up 0.58% year-on-year, while the non-recurring net profit surged by 84.75% to 11.70 million yuan [3] - The company has a debt ratio of 22.29% and reported investment income of 2.96 million yuan, with financial expenses amounting to -6.64 million yuan [3] Group 2: Market Indicators - Shangrong Medical's total market capitalization stands at 4.058 billion yuan, significantly lower than the industry average of 12.064 billion yuan, ranking 93rd out of 123 in the medical device sector [3] - The company's net assets are valued at 2.789 billion yuan, compared to the industry average of 3.899 billion yuan, ranking 54th [3] - The price-to-earnings ratio (P/E) is 72.66, slightly above the industry average of 70.48, while the price-to-book ratio (P/B) is 1.54, significantly lower than the industry average of 4.02, ranking 18th [3] - Shangrong Medical's gross margin is 15.27%, well below the industry average of 51.34%, ranking 119th, and the net margin is 6.09%, compared to the industry average of 10.86%, ranking 83rd [3] - The return on equity (ROE) is 0.53%, lower than the industry average of 1.19%, ranking 85th [3] Group 3: Capital Flow Analysis - On August 13, 2025, the net outflow of main funds was 30.36 million yuan, accounting for 4.03% of the total transaction value, while retail investors saw a net inflow of 18.44 million yuan, representing 2.45% of the total [1][2] - Over the past five days, the stock experienced fluctuations in capital flow, with notable net inflows and outflows from different investor categories [2]